The Severity of COVID-19 in Systemic Lupus Erythematosus Patient.

The Severity of COVID-19 in Systemic Lupus Erythematosus Patient.

Publication date: Dec 20, 2024

As of early October 2020, the COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, resulted in approximately 35 million cases and one million fatalities worldwide. Systemic lupus erythematosus (SLE) is an autoimmune disease marked by the generation of pathogenic autoantibodies and a lack of tolerance to nuclear self-antigens. Hypocomple-mentemia, or an abnormal blood complement deficit, is a reliable predictor of infection in SLE patients. Moreover, it has been found that immunoglobulin (Ig), particularly IgG and IgM, is lowered in SLE patients, which may be a factor in their heightened susceptibility to infection. Bloodstream autoantibodies, lymphopenia, aberrant T cells, proinflammatory cytokines, and impaired regulatory systems all lead to an immune response that is aberrant in lupus patients. SLE patients exhibit impaired CD8 T cell responses, including abnormal phagocytosis and chemotaxis. Recent study has shown that COVID-19 infections significantly boost type I inter-feron responses. Patients with SLE and Covid-19 infection typically get immune-suppressing drugs viz corticosteroids, Janus kinase inhibitors (JAK), and tocilizumab, which improve their immune systems and diminution susceptible to Covid-19 infections.

Concepts Keywords
Bloodstream autoantibodies
Coronavirus COVID-19
October cytokine storm.
Phagocytosis hypocomplementemia
Reliable immuno-suppression
SARS-Co-V-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Systemic Lupus Erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH autoimmune disease
disease IDO blood
disease MESH infection
disease IDO susceptibility
disease MESH lymphopenia
disease IDO immune response
disease IDO cell
drug DRUGBANK Tocilizumab
disease MESH cytokine storm

Original Article

(Visited 2 times, 1 visits today)